Abstract:DNA-binding proteins including transcription factors (TFs) play essential roles in gene transcription and DNA replication and repair during normal organ development and pathogenesis of diseases such as cancer, cardiovascular disease and obesity, deeming to be a large repertoire of attractive therapeutic targets. However, this group of proteins are generally considered undruggable as they lack an enzymatic catalytic site or a ligand binding pocket. PROteolysis-TArgeting Chimera (PROTAC) technology has been developed by engineering a bifunctional small molecule chimera to bring a protein of interest (POI) to the proximity of an E3 ubiquitin ligase, thus inducing the ubiquitination of POI and further degradation through proteasome pathway. Here we report the development of Oligonucleotide-based PROTAC (O’PROTACs), a class of noncanonical PROTACs in which a TF-recognizing double-stranded oligonucleotide is incorporated as a binding moiety of POI. We demonstrate that O’PROTACs of ERG and LEF1, two highly cancer-related transcription factors selectively promote degradation of these proteins and inhibit their transcriptional activity in cancer cells. The programmable nature of O’PROTACs indicates that this approach is applicable to destruct other TFs. O’PROTACs not only can serve as a research tool, but also can be harnessed as a therapeutic arsenal to target DNA binding proteins for effective treatment of diseases such as cancer. ### Competing Interest Statement The authors have declared no competing interest.

Destruction of DNA-Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG (Adv. Sci. 20/2021)

Destruction of DNA‐Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG

Destruction of DNA-binding proteins by programmable O’PROTAC: Oligonucleotide-based PROTAC

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

TF-PROTACs Enable Targeted Degradation of Transcription Factors.

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

ZIF-90-loaded DNAzyme-responsive PROTAC for the Self-Powered Degradation of NF-κB

Targeting Undruggable Transcription Factors with PROTACs: Advances and Perspectives

DNA framework-engineered chimeras platform enables selectively targeted protein degradation

Precise Modulation of Protein Degradation by Smart PROTACs

Small Molecule PROTACs in Targeted Therapy: an Emerging Strategy to Induce Protein Degradation.

A modular PROTAC design for target destruction using a degradation signal based on a single amino acid

bioPROTACs as versatile modulators of intracellular therapeutic targets including proliferating cell nuclear antigen (PCNA)

Stimuli-activatable PROTACs for precise protein degradation and cancer therapy

Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation

In Vivo Target Protein Degradation Induced by PROTACs Based on E3 Ligase DCAF15

DNA-templated spatially controlled proteolysis targeting chimeras for CyclinD1-CDK4/6 complex protein degradation

Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety

Inducible Degradation of Oncogenic Nucleolin Using an Aptamer-Based PROTAC

PROTACs technology for targeting non-oncoproteins: Advances and perspectives

The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination.